跳至主要内容
临床试验/NCT07597863
NCT07597863尚未招募不适用

Optimizing Pharmacotherapy in Severe Mental Illness and Substance Use Disorder; Integrating a Clinical Pharmacist Into FACT Teams

Sykehuset Innlandet HF1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2026年5月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
尚未招募
入组人数
160
试验地点
1
主要终点
Patient-reported health related quality of life

研究概览

简要总结

The study aims to evaluate the impact of integrating a clinical pharmacist into Flexible Assertive Community (FACT) teams on health-related quality of life and pharmacotherapy for individuals with severe mental illness and substance use disorders. This is a pragmatic effectiveness study using a stepped wedge cluster randomized trial design. Four FACT teams from FACT Innlandet will serve as clusters, transitioning from standard care (control) to intervention in a randomized sequence. The intervention involves integrating a clinical pharmacist into the interdisciplinary FACT teams. Participants will be adults (over 18 years old), receiving treatment from participating FACT teams, diagnosed with severe mental illness or substance use disorder and prescribed at least one psychotropic medication. Exclusion criteria include inability to provide informed consent, planned discharge within the first three months of period 1, or inability to communicate in Norwegian or English. The control group receives standard care provided by FACT teams. The intervention group will have a clinical pharmacist integrated into the FACT team performing medication reconciliation, comprehensive medication reviews, patient counselling, and interdisciplinary discussions to resolve medication-related problems. A sample size of 160 patients is estimated based on an effect size of 0.25, 80% power and alpha=0.05. The primary endpoint is change in patient-reported health related quality of life, measured using the EuroQoL-5 dimensions-5 levels (EQ-5D-5L) and Visual Analog Scale, EQ-VAS scores from baseline to the end of the intervention.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age over 18 years old
  • Included in and receiving treatment from a participating FACT team
  • Diagnosed with severe mental illness and/or substance use disorder
  • Prescribed one or more psychotropic medication
  • Signed informed consent

排除标准

  • Patients not being competent or have the decision-making capacity to consent
  • Planned discharge from the team within the first three months of period 1
  • Patients not able to communicate in Norwegian or English

研究组 & 干预措施

Control phase

No Intervention

Intervention

Experimental

干预措施: Clinical Pharmacist Intervention (Other)

结局指标

主要结局

Patient-reported health related quality of life

时间窗: EQ-5D-5L and EQ VAS will be assessed in period 1 (baseline (time 0-4 months), period 2 (4-8 months), period 3 (8-12 months), period 4 (12-16 months, period 5 (16-20 months) and period 6 (20-24 months).

Questionnaire EuroQoL EQ-5D-5L and EQ-VAS. The results from the questionnaire EQ-5D-5L will be reported as a five digit health profile, an index value calculated using the Norwegian value set with a score between 0 and 1, where 0 is death and 1 is full health. The EQ-VAS (visual analogue scale) is reported on a scale between 0-100 where 0 is worst imaginable health and 100 is best imaginable health.

次要结局

  • Change in patient reported psychiatric burden(The SCL-90-R will be assessed at control conditions and after completion of the pharmacist intervention per patient, estimated median of 2 months.)
  • Change in patient reported attitudes towards pharmacological treatment(The BMQ will be assesed at control conditions and after completion of the pharmacist intervention per patient, estimated median of 2 months.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Anne Landheim

Professor

Sykehuset Innlandet HF

研究点 (1)

Loading locations...

相似试验